Spirulina and Ferritin Heavy Chain (FTH1): Nrf2-Driven Iron Sequestration and Ferroptosis Protection

Ferritin Structure: Heavy Chain Ferroxidase and Light Chain Nucleation

Ferritin is a 24-subunit hollow protein nanocage with an outer diameter of ~12 nm and an inner cavity capable of storing up to 4,500 iron atoms as a ferrihydrite mineral core. The cage is assembled from two types of subunit: ferritin heavy chain (FTH1; FHC; H-ferritin; encoded by FTH1 on chromosome 11q13; 21 kDa; 183 amino acids) and ferritin light chain (FTL; FLC; L-ferritin; chromosome 19q13; 19 kDa; 175 amino acids). The two subunits share ~55% sequence identity and assemble in variable H:L ratios depending on tissue and oxidative context. FTH1 carries the ferroxidase centre: a dinuclear iron-binding site at positions His65, Glu27, Glu62, His65, Glu107, and Gln141 (conserved across species). This ferroxidase activity oxidises Fe²⁺ (ferrous iron; soluble; Fenton-reactive) to Fe³⁺ (ferric iron; insoluble when mineralised; non-reactive with H2O2) using molecular oxygen as the electron acceptor (2 Fe²⁺+ O2 + 4H+ → 2 Fe³⁺+ 2 H2O), with peroxodiferric intermediate formation. Crucially, it is this enzymatic step that detoxifies the labile iron pool (LIP; the chelatable, redox-active cytosolic iron; approximately 0.2–1.5 μM in most cell types under normal conditions). FTL, lacking ferroxidase activity, instead provides nucleation sites that accelerate iron core mineralisation once Fe³⁺enters the cavity. Tissues requiring high iron storage capacity (liver, spleen, bone marrow) express predominantly L-rich ferritin; tissues requiring rapid iron detoxification under oxidative stress (heart, brain, kidney) express predominantly H-rich ferritin.

Nrf2/ARE-Driven FTH1 Induction and HMOX1 Co-regulation

The FTH1 gene promoter contains multiple antioxidant response elements (AREs; consensus 5′-TGACnnnGC-3′; Nrf2/Maf heterodimer binding sites). Nrf2 activation — classically by electrophilic Keap1 modifiers, but also by sulforaphane, quercetin, and phycocyanobilin (spirulina’s chromophore, which modifies Cys151 and Cys273 of Keap1 as a biliverdin analogue) — drives FTH1 mRNA upregulation by 2–5-fold within 4–8 hours. This induction is among the more robust Nrf2 targets; its magnitude is comparable to the co-induced antioxidant genes GCLC (glutamate-cysteine ligase; rate-limiting for GSH synthesis) and NQO1 (NAD(P)H quinone oxidoreductase 1). Critically, heme oxygenase 1 (HMOX1; HO-1), the most strongly Nrf2-induced gene (upregulation 5–20-fold), catalyses the degradation of heme to biliverdin, CO, and free iron. The free iron released by HMOX1 is immediately handled by the concomitantly upregulated FTH1: this HMOX1-FTH1 co-induction is a co-ordinated two-step system that destroys the redox-active heme molecule and safely mineralises the iron it contained. Spirulina’s Nrf2 activation thus induces both components simultaneously, making the anti-Fenton effect substantially greater than either enzyme alone would achieve. Quantitatively, spirulina extracts in HepG2 hepatocyte models have been reported to increase FTH1 protein by 40–80% and HMOX1 protein by 60–120% within 24 hours at concentrations equivalent to ~5–10 g clinical doses extrapolated from plasma phycocyanobilin estimates.

Nuclear Ferritin and DNA Protection from Fenton Chemistry

A fraction of cellular FTH1 localises to the nucleus. Nuclear H-ferritin was initially described in erythroid cells but has since been identified in hepatocytes, neurons, and several tumour cell lines. Its nuclear localisation signal appears to be revealed post-translationally under oxidative stress conditions, facilitating import via the importinα/β pathway. The function of nuclear ferritin is mechanistically straightforward: DNA is in intimate contact with the nucleus’s ionic environment, including iron ions that co-precipitate with chromatin. Fe²⁺in the vicinity of DNA participates in site-specific Fenton reactions (Fe²⁺+ H2O2 → Fe³⁺ + OH• + OH⁻; the hydroxyl radical reacts with DNA at diffusion-limited rates within nanometres of its production site), generating 8-oxo-2′-deoxyguanosine (8-oxodG; mutagenic guanine oxidation product), single-strand breaks, and abasic sites. Nuclear ferritin reduces the nuclear labile iron pool and thereby suppresses DNA strand-break frequency. Studies using chelation to selectively lower nuclear iron have confirmed that nuclear LIP is a significant driver of oxidative DNA damage under conditions of iron overload or oxidative stress. Nrf2-driven nuclear FTH1 induction represents a transcriptionally regulated form of DNA protection that operates independently of, and additively with, the classic nucleotide excision repair (NER) and base excision repair (BER) DNA repair pathways.

FTH1 as a Ferroptosis Brake: Limiting the Labile Iron Pool

Ferroptosis is a regulated, non-apoptotic cell death modality characterised by iron-dependent lipid peroxidation, driven by the accumulation of phospholipid hydroperoxides (PLOOH; particularly arachidonate-PE hydroperoxides at the inner leaflet of the plasma membrane). The two principal brakes on ferroptosis are GPX4 (glutathione peroxidase 4; the only glutathione peroxidase capable of reducing PLOOH in situ within membranes, using GSH as the electron donor to convert PLOOH to the corresponding alcohol) and the FTH1-maintained low labile iron pool. The mechanistic link between LIP and ferroptosis is that free Fe²⁺catalyses lipid peroxide propagation via Fenton-type reactions with lipid peroxyl radicals and via lipoxygenase (LOX; ALOX15/ALOX5 require non-heme iron for activity) activation. Ferroptosis inducers such as erastin (inhibits system Xc−, the cystine/glutamate antiporter; reduces cysteine → GSH depletion → GPX4 inactivation) and RSL3 (direct GPX4 inhibitor; alkylates the active-site selenocysteine) dramatically increase LIP by freeing iron from ferritin through an autophagy pathway termed ferritinophagy (NCOA4/ferritinophagy receptor; NCOA4 binds FTH1 at Arg23, Lys24; delivers ferritin to autolysosomes; ferritin is degraded; iron is released; LIP rises). Upregulation of FTH1 by Nrf2 resists ferroptosis by maintaining low LIP and by directly outcompeting NCOA4-ferritinophagy: more total ferritin protein means that the same NCOA4-mediated degradation rate delivers proportionately less iron. GPX4 and FTH1 are thus the two Nrf2-co-regulated ferroptosis brakes working in tandem: GPX4 (also an Nrf2 target, via a proximal ARE; upregulated ~50–100% by strong Nrf2 activators) detoxifies the lipid hydroperoxides that do form, while FTH1 reduces the iron-dependent propagation rate.

Spirulina’s Iron Content: The Provision vs Sequestration Paradox

Spirulina is among the most iron-dense plant-based foods: dry powder contains approximately 28–35 mg iron per 100 g, meaning a 5 g serving provides roughly 1.5–1.8 mg iron, 8–20% of daily requirements depending on the RDA applied and sex. This creates a surface-level paradox: spirulina provides substantial iron while simultaneously activating Nrf2/FTH1 to sequester iron. The resolution is mechanistically satisfying. Iron provided by digested spirulina enters the portal circulation and hepatocytes as Fe²⁺ (via DMT1/ SLC11A2 in enterocytes or ferroportin-exported from enterocytes as Fe²⁺bound to transferrin). Inside hepatocytes, where FTH1 induction by phycocyanobilin is strongest, the iron is efficiently captured by upregulated ferritin, preventing LIP accumulation that would otherwise cause oxidative stress. The net effect is iron delivery with unusually low oxidative cost — a form of “clean iron provision.” The bioavailability of spirulina iron, while commonly cited as high, is contested: non-heme iron bioavailability is typically 5–15%, and spirulina’s unique protein matrix may not dramatically improve this estimate. What is clearer is that the concomitant Nrf2-FTH1 upregulation means that whatever iron is absorbed is handled in a more protected cellular environment compared with inorganic iron salt supplementation, which lacks this co-regulatory package.

Practical Takeaway

Spirulina’s FTH1-raising effect has practical relevance in three overlapping populations. People with mild iron deficiency may benefit from spirulina’s combination of modest iron provision and FTH1-protective handling, though severely anaemic individuals should not rely on spirulina as their primary iron source and should use supplemental ferrous iron or ferric polymaltose alongside a physician’s guidance. People at risk of ferroptosis-associated tissue damage — including those with neurodegenerative conditions (ferroptosis is implicated in Parkinson’s and ALS pathology), ischaemia-reperfusion injury, or haemochromatosis-adjacent iron overload states — have a mechanistically plausible rationale for Nrf2/FTH1 upregulation through dietary means, including spirulina. Finally, cancer patients on therapies that induce ferroptosis as part of their mechanism (certain immunotherapy combinations have been shown to promote ferroptosis in tumour cells) should be aware that strong Nrf2 activators including spirulina could theoretically protect cancer cells alongside normal cells; this is a theoretical concern, not a documented interaction, but warrants transparency with oncologists. For otherwise healthy adults, the FTH1/ferroptosis protection afforded by spirulina’s Nrf2 activation represents a genuine, mechanistically grounded benefit operating quietly beneath the more headline-visible antioxidant and anti-inflammatory effects.